肝硬化并发急性肾损伤诊治进展

doi:10.3969/j.issn.1672-5069.2022.06.003

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (6): 768-771.doi: 10.3969/j.issn.1672-5069.2022.06.003

肝硬化并发急性肾损伤诊治进展

韩芳, 李佳峥, 南月敏

050051 石家庄市河北医科大学第三医院中西医结合肝病科/胃肠病学重点学科/河北省慢性肝病肝纤维化机制研究重点实验室

收稿日期:2022-09-02 出版日期:2022-11-10 发布日期:2022-11-22
通讯作者: 南月敏,E-mail:nanyuemin@163.com
作者简介:韩芳,女,38岁,医学硕士,主治医师。主要从事慢性肝炎、肝硬化和肝衰竭诊治研究。E-mail:hanfangfang1124@163.com

Management of acute kidney injury in patients with livercirrhosis

Han Fang, Li Jiazheng, Nan Yuemin

Provincial Key Laboratory of study on Mechanism of Hepatic Fibrosis in Chronic Liver Diseases, Department of Traditional and Western Medical Hepatology, Third Hospital, Hebei Medical University,Shijiazhuang 050051,China

Received:2022-09-02 Online:2022-11-10 Published:2022-11-22

摘要/Abstract

关键词: 肝硬化, 急性肾损伤, 肝肾综合征, 诊断, 治疗

Key words: Liver cirrhosis, Acute kidney injury, Hepatorenal syndrome, Diagnostic criteria, Management

韩芳, 李佳峥, 南月敏. 肝硬化并发急性肾损伤诊治进展[J]. 实用肝脏病杂志, 2022, 25(6): 768-771.

Han Fang, Li Jiazheng, Nan Yuemin. Management of acute kidney injury in patients with livercirrhosis[J]. Journal of Practical Hepatology, 2022, 25(6): 768-771.

[1] Ginès P, Solà E, Angeli P, et al. Hepatorenal syndrome. Nat Rev Dis Primers, 2018, 4(1): 23-39.
[2] Huelin P, Solà E, Elia C, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study. Hepatology, 2019, 70(1): 319-333.
[3] Tandon P, James MT, Abraldes JG, et al. Relevance of new definitions to incidence and prognosis of acute kidney injury in hospitalized patients with cirrhosis: a retrospective population-based cohort study. PLoS One, 2016, 11(8): e0160394- e0160405.
[4] 王文娟, 宋琦,丁惠国. 肝硬化患者急性肾损伤的临床特点及危险因素分析. 中华内科杂志, 2018, 57(12): 912-916.
[5] 王洪玲,田洁,韩涛.失代偿性肝硬化伴发急性肾损伤的危险因素分析. 中华肝脏病杂志, 2014,22(6): 420-424
[6] Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. Brit Med J,2020,370: m2687-m2702.
[7] Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol, 2015, 62(4): 968-974.
[8] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74(2): 1014-1048.
[9] Gifford F J,Morling J R, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther, 2017,45(5):593-603.
[10] Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology, 2016, 63(3): 983-992.
[11] Song T,Rössle M, He F, et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis,2018, 50(4): 323-330.
[12] European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. JHepatol, 2018, 69(2): 406-460.

[1]	韩涛, 刘艳迪, 胡家轩. 肝病合并肾损伤临床诊治新进展[J]. 实用肝脏病杂志, 2022, 25(6): 761-763.
[2]	蒋莹莹, 丁惠国. 肝硬化并发急性肾损伤临床管理现状与挑战[J]. 实用肝脏病杂志, 2022, 25(6): 764-767.
[3]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[4]	吴凤萍, 崔丹丹, 王怡恺, 李梅, 刘晨瑞, 南希, 贾晓黎, 党双锁. 血清BAFF预测聚乙二醇干扰素-α治疗非活动性HBsAg携带者临床治愈的效能分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 780-783.
[5]	许海玲, 秦刚, 薛红, 章颖. 艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 788-791.
[6]	赵资德, 吴令杰, 张海生, 陈瑞烈. 纠正低蛋白血症减少抗结核药物性肝损伤发生临床研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 792-795.
[7]	孙峥, 王笑烨, 袁景, 梁丽. 达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 796-799.
[8]	蔡勇, 李璟, 欧琴. 2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 800-803.
[9]	孙凌, 杭玮, 邓国忠. 二甲双胍联合吡格列酮治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 804-807.
[10]	王玉梅, 袁向东, 刘玉玲, 赵子瑜. 提示肥胖症儿童/青少年存在非酒精性脂肪性肝炎的指标分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 808-811.
[11]	贺锦帆, 姚佳, 赵强, 王娟, 白津佳, 赵凝慧. 双重血浆分子吸附系统治疗肝衰竭患者发生血管迷走神经反应相关因素分析及其处理对策研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 828-831.
[12]	沈亦亮, 沈冬元, 陈永莹, 江凯, 朱逸明, 葛尚. 肝硬化患者肝内LR-3类结节恶变风险评估及预测模型的建立^*[J]. 实用肝脏病杂志, 2022, 25(6): 836-839.
[13]	徐超, 李兰, 罗东, 赵海云, 彭飞. TIPS术治疗的肝硬化并发EVB患者医院内死亡风险预测模型的构建与应用^*[J]. 实用肝脏病杂志, 2022, 25(6): 840-843.
[14]	林秀慧, 李南, 张娇珍, 符庆忠, 林秀华. 慢性HBV感染者外周血PNPLA3/PRKAA1基因多态性与肝硬化发生关系研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 844-847.
[15]	朱海艳, 范晓棠. 肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J]. 实用肝脏病杂志, 2022, 25(6): 848-852.

肝硬化并发急性肾损伤诊治进展

Management of acute kidney injury in patients with livercirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价